M. Ozbalak Et Al. , "Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience," HEMATOLOGICAL ONCOLOGY , vol.30, no.2, pp.76-81, 2012
Ozbalak, M. Et Al. 2012. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience. HEMATOLOGICAL ONCOLOGY , vol.30, no.2 , 76-81.
Ozbalak, M., Cetiner, M., Bekoz, H., BİRTAŞ ATEŞOĞLU, E., Ar, C., Salihoglu, A., ... Tuzuner, N.(2012). Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience. HEMATOLOGICAL ONCOLOGY , vol.30, no.2, 76-81.
Ozbalak, Murat Et Al. "Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience," HEMATOLOGICAL ONCOLOGY , vol.30, no.2, 76-81, 2012
Ozbalak, Murat Et Al. "Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience." HEMATOLOGICAL ONCOLOGY , vol.30, no.2, pp.76-81, 2012
Ozbalak, M. Et Al. (2012) . "Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience." HEMATOLOGICAL ONCOLOGY , vol.30, no.2, pp.76-81.
@article{article, author={Murat Ozbalak Et Al. }, title={Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience}, journal={HEMATOLOGICAL ONCOLOGY}, year=2012, pages={76-81} }